CLINICAL ROLE -
Benefit of Adjuvant Abemaciclib in High-Risk Early Breast Cancer Is Sustained at 5 Years
The therapy sustained IDFS benefit compared with ET alone.
Phase 3 Data Show Tebentafusp Provides Long-Term Survival Benefit in Patients With Metastatic Uveal Melanoma
The results confirm tebentafusp as a standard of care.
Nivolumab Plus Chemotherapy Treatment Followed by Surgery Improves EFS in Patients With NSCLC
The results support perioperative nivolumab as a potential new treatment option.
Pharmacists Can Help Address Treatment Challenges for Patients With Cholangiocarcinoma
Treatment options can be limited for this patient population.
Use of Recurrence Score Combined With Clinical, Genetic Factors Improves Prognostic Ability in HR+/ HER2– Early Breast Cancer
There is a prognostic impact of clinical and immunohistochemistry markers.
Medication Adherence to BTK Inhibitors Can Pose Challenges for Patients With CLL
Although treatment is effective, AEs remain difficult for patients.
Palliative Care Is Not (Necessarily) the End
Hospice care is only a part of palliative care services.
Alternative Funding Programs Affect Our Most Vulnerable Patient Populations
AFPs limit access to provider-prescribed specialty medications.
Adverse Effects Impact Treatment Selection for VEGF-Targeted Oral TKIs in Metastatic RCC
Axitinib, cabozantinib, and lenvatinib are first-line treatment options.
Exploring the Landscape of Gene Therapy
An overview of how gene therapy has evolved since its inception, current applications, and emerging challenges.
New BiTE Agents Provide Effective Options for Treatment of Relapsed/Refractory Multiple Myeloma
Seven new agents have received FDA approval since October 2022.
Alternative Funding Programs Present Ethical, Legal Considerations
Exclusions of medication are often focused on high-cost specialty formularies, resulting in fewer options for patients who need them.
